Neoleukin Therapeutics Overview

Neoleukin Therapeutics Other Income Expense Net

Other Income/Expense Net for NLTX.

Quarterly Other Income/Expense

$2.42M

↓ 26.19% YoY

As of Mar 31, 2026

Annual Other Income/Expense (TTM)

$12.12M

↑ 6.47% YoY

Trailing 12 months ending Mar 31, 2026

Average Other Income/Expense (Comparison Companies)

Other Income Expense Net History

Other Income Expense Net Comparison

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin